Menu
Search
|

Menu

Close
X

VistaGen Therapeutics Inc VTGN.OQ (NASDAQ Stock Exchange Capital Market)

1.86 USD
-0.07 (-3.63%)
As of 2:00 PM EST
chart
Previous Close 1.93
Open 1.90
Volume 18,354
3m Avg Volume 66,345
Today’s High 1.90
Today’s Low 1.80
52 Week High 2.65
52 Week Low 0.69
Shares Outstanding (mil) 31.06
Market Capitalization (mil) 60.41
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
1
FY16
0
FY15
0
EPS (USD)
FY19
-0.494
FY18
-1.250
FY17
-1.597
FY16
-30.893
FY15
-10.371
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
--
22.95
Price to Book (MRQ)
vs sector
13.93
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
3.17
15.47
LT Debt to Equity (MRQ)
vs sector
0.20
11.13
Return on Investment (TTM)
vs sector
-450.63
13.00
Return on Equity (TTM)
vs sector
-1,733.30
14.69

EXECUTIVE LEADERSHIP

H. Snodgrass
President, Chief Scientific Officer, Director, Since 2011
Salary: $305,000.00
Bonus: --
Shawn Singh
Chief Executive Officer, Director, Since 2011
Salary: $347,500.00
Bonus: --
Jerrold Dotson
Chief Financial Officer, Vice President, Company Secretary, Since 2014
Salary: $250,000.00
Bonus: --
Mark Smith
Chief Medical Officer, Since 2016
Salary: --
Bonus: --
Jerry Gin
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

343 Allerton Ave
SOUTH SAN FRANCISCO   CA   94080-4816

Phone: +1650.5773600

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.

SPONSORED STORIES